Cargando…

Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression

Adjuvant durvalumab after chemoradiotherapy (CRT) is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). A post hoc exploratory analysis of PACIFIC revealed no OS benefit in the PD-L1 < 1% subgroup. This retrospective analysis assesses the real-world impact of durv...

Descripción completa

Detalles Bibliográficos
Autores principales: Denault, Marie-Hélène, Feng, Jamie, Kuang, Shelley, Shokoohi, Aria, Leung, Bonnie, Liu, Mitchell, Berthelet, Eric, Laskin, Janessa, Sun, Sophie, Zhang, Tina, Ho, Cheryl, Melosky, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453050/
https://www.ncbi.nlm.nih.gov/pubmed/37623024
http://dx.doi.org/10.3390/curroncol30080543
_version_ 1785095825705140224
author Denault, Marie-Hélène
Feng, Jamie
Kuang, Shelley
Shokoohi, Aria
Leung, Bonnie
Liu, Mitchell
Berthelet, Eric
Laskin, Janessa
Sun, Sophie
Zhang, Tina
Ho, Cheryl
Melosky, Barbara
author_facet Denault, Marie-Hélène
Feng, Jamie
Kuang, Shelley
Shokoohi, Aria
Leung, Bonnie
Liu, Mitchell
Berthelet, Eric
Laskin, Janessa
Sun, Sophie
Zhang, Tina
Ho, Cheryl
Melosky, Barbara
author_sort Denault, Marie-Hélène
collection PubMed
description Adjuvant durvalumab after chemoradiotherapy (CRT) is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). A post hoc exploratory analysis of PACIFIC revealed no OS benefit in the PD-L1 < 1% subgroup. This retrospective analysis assesses the real-world impact of durvalumab on OS according to PD-L1 tumor proportion score (TPS). Patients with stage III, unresectable NSCLC treated by CRT, with available PD-L1 TPS, from 1 March 2018 to 31 December 2020, at BC Cancer, British Columbia, Canada were included. Patients were divided into two groups, CRT + durvalumab and CRT alone. OS and PFS were analyzed in the PD-L1 ≥ 1% and <1% subgroups. A total of 134 patients were included in the CRT + durvalumab group and 117, in the CRT alone group. Median OS was 35.9 months in the CRT + durvalumab group and 27.4 months in the CRT alone group [HR 0.59 (95% CI 0.42–0.83), p = 0.003]. Durvalumab improved OS in the PD-L1 ≥ 1% [HR 0.53 (95% CI 0.34–0.81), p = 0.003, n = 175], but not in the <1% subgroup [HR 0.79 (95% CI 0.44–1.42), p = 0.4, n = 76]. This retrospective study demonstrates a statistically significant improvement in OS associated with durvalumab after CRT in PD-L1 ≥ 1%, but not PD-L1 < 1% NSCLC. Variables not accounted for may have biased the survival analysis. A prospective study would bring more insight.
format Online
Article
Text
id pubmed-10453050
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104530502023-08-26 Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression Denault, Marie-Hélène Feng, Jamie Kuang, Shelley Shokoohi, Aria Leung, Bonnie Liu, Mitchell Berthelet, Eric Laskin, Janessa Sun, Sophie Zhang, Tina Ho, Cheryl Melosky, Barbara Curr Oncol Article Adjuvant durvalumab after chemoradiotherapy (CRT) is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). A post hoc exploratory analysis of PACIFIC revealed no OS benefit in the PD-L1 < 1% subgroup. This retrospective analysis assesses the real-world impact of durvalumab on OS according to PD-L1 tumor proportion score (TPS). Patients with stage III, unresectable NSCLC treated by CRT, with available PD-L1 TPS, from 1 March 2018 to 31 December 2020, at BC Cancer, British Columbia, Canada were included. Patients were divided into two groups, CRT + durvalumab and CRT alone. OS and PFS were analyzed in the PD-L1 ≥ 1% and <1% subgroups. A total of 134 patients were included in the CRT + durvalumab group and 117, in the CRT alone group. Median OS was 35.9 months in the CRT + durvalumab group and 27.4 months in the CRT alone group [HR 0.59 (95% CI 0.42–0.83), p = 0.003]. Durvalumab improved OS in the PD-L1 ≥ 1% [HR 0.53 (95% CI 0.34–0.81), p = 0.003, n = 175], but not in the <1% subgroup [HR 0.79 (95% CI 0.44–1.42), p = 0.4, n = 76]. This retrospective study demonstrates a statistically significant improvement in OS associated with durvalumab after CRT in PD-L1 ≥ 1%, but not PD-L1 < 1% NSCLC. Variables not accounted for may have biased the survival analysis. A prospective study would bring more insight. MDPI 2023-08-08 /pmc/articles/PMC10453050/ /pubmed/37623024 http://dx.doi.org/10.3390/curroncol30080543 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Denault, Marie-Hélène
Feng, Jamie
Kuang, Shelley
Shokoohi, Aria
Leung, Bonnie
Liu, Mitchell
Berthelet, Eric
Laskin, Janessa
Sun, Sophie
Zhang, Tina
Ho, Cheryl
Melosky, Barbara
Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression
title Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression
title_full Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression
title_fullStr Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression
title_full_unstemmed Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression
title_short Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression
title_sort beyond pacific: real-world outcomes of adjuvant durvalumab according to treatment received and pd-l1 expression
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453050/
https://www.ncbi.nlm.nih.gov/pubmed/37623024
http://dx.doi.org/10.3390/curroncol30080543
work_keys_str_mv AT denaultmariehelene beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression
AT fengjamie beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression
AT kuangshelley beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression
AT shokoohiaria beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression
AT leungbonnie beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression
AT liumitchell beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression
AT bertheleteric beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression
AT laskinjanessa beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression
AT sunsophie beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression
AT zhangtina beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression
AT hocheryl beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression
AT meloskybarbara beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression